INOVIO Doses First Participant In Phase 2 Trial For DNA Vaccine Against Middle East Respiratory Syndrome (MERS)
eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, announced today the initiation of dosing in the Phase 2a